NCT01457339View on ClinicalTrials.gov

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 21, 2011

Primary Completion Date

January 20, 2012

Study Completion Date

January 20, 2012

Conditions
Schizophrenia
Interventions
DRUG

SPD489 (Lisdexamfetamine dimesylate)

SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.

DRUG

Placebo

Placebo Capsule(s) for oral use taken once daily for 30 days

Trial Locations (2)

90806

Collaborative Neuroscience Network, Inc, Long Beach

91206

California Clinical Trials, Glendale

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT01457339 - Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia | Biotech Hunter | Biotech Hunter